Human Genome Sciences: Novel Product Line, Significant Debt Reduction

By Kraken:Last month, GlaxoSmithKline (GSK) made an offer to Human Genome Sciences (HGSI) in a buyout of the company for $13 a share. The stock price of HGSI nearly doubled on the news. (Click to enlarge)

Todd Johnson submits:Human Genome Sciences (HGSI) is finally coming to market with the full FDA approved medication. The company's early years hype, and later years near-death stock experience, can all be viewed in perspective.

Trader Mark submits:I really tried to be more of a traditional mutual fund manager the past 2 weeks, and not trade as much - let the winners run (yada yada yada). Thus far, for many positions I have sat on my hands with, all I've been rewarded with by not locking in gains are stocks that have completely retraced their moves up, and all my unrealized gains in those stocks have been vanquished.

By Helix Investment Management:Headlines in the biotechnology sector are frequently dominated by M&A news, and as of April 19, there is a new M&A headline to discuss and analyze.

By Robert Broens: Shares of Human Genome Sciences (HGSI) almost doubled today after GlaxoSmithKline made a $13 offer for the company. Shares ended the day 98% higher to close at $14.17

By VFC: Even on a day when the DOW drops 300 points at the open, there's sure to be a good news story somewhere.

Zacks.com submits: We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $29.00.

Andrew Wilkinson submits: Human Genome Sciences, Inc. (HGSI) – Shares in Human Genome Sciences are up 8.9% to trade around $26.49 in the final hour of the trading session on speculation the firm could become an attractive takeover target if its lupus drug treatment, Benlysta, wins approval next month.